Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Purchased by Lingotto Investment Management LLP

Lingotto Investment Management LLP grew its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,192,388 shares of the company’s stock after acquiring an additional 688,862 shares during the quarter. Teva Pharmaceutical Industries comprises about 16.1% of Lingotto Investment Management LLP’s holdings, making the stock its 2nd largest position. Lingotto Investment Management LLP’s holdings in Teva Pharmaceutical Industries were worth $599,320,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Creative Planning grew its stake in shares of Teva Pharmaceutical Industries by 4.5% during the 3rd quarter. Creative Planning now owns 42,815 shares of the company’s stock valued at $772,000 after buying an additional 1,863 shares during the period. Private Advisor Group LLC raised its holdings in Teva Pharmaceutical Industries by 12.9% in the third quarter. Private Advisor Group LLC now owns 26,104 shares of the company’s stock valued at $470,000 after buying an additional 2,990 shares during the period. Diversify Advisory Services LLC lifted its position in Teva Pharmaceutical Industries by 95.3% during the third quarter. Diversify Advisory Services LLC now owns 19,859 shares of the company’s stock valued at $365,000 after buying an additional 9,693 shares in the last quarter. Diversify Wealth Management LLC purchased a new stake in Teva Pharmaceutical Industries during the third quarter worth approximately $640,000. Finally, Gladstone Institutional Advisory LLC raised its stake in shares of Teva Pharmaceutical Industries by 847.5% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 143,939 shares of the company’s stock valued at $2,594,000 after acquiring an additional 128,748 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 286,000 shares of the firm’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the transaction, the director now owns 695,000 shares of the company’s stock, valued at $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.55% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $16.59 on Wednesday. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries Limited has a 12-month low of $12.51 and a 12-month high of $22.80. The business has a 50 day simple moving average of $19.93 and a 200 day simple moving average of $18.50. The firm has a market capitalization of $18.79 billion, a price-to-earnings ratio of -11.44, a price-to-earnings-growth ratio of 1.44 and a beta of 0.71.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on TEVA shares. Piper Sandler increased their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. Barclays cut their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. UBS Group cut their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Finally, StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.57.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.